Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Norfolk Southern Corporation (NSC) vs Viatris Inc (VTRS) Price & Performance

Norfolk Southern CorporationTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Norfolk Southern Corporation vs Viatris Inc — how do they compare? Norfolk Southern Corporation trades at $317.79 (market cap $71.20B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Norfolk Southern Corporation is far larger — about 3.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and Viatris Inc for 57 Days on average.

NSCVTRS
Market Cap
$71.20B$20.03B
Volume
555,24814,109,977
Sector
IndustrialsHealth
52-Week High
$352.98$18.27
52-Week Low
$278.19$9.74
Typical Hold Time
33 Days57 Days
Enterprise Value
$86.75B$32.15B
Dividend Yield
1.7%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Norfolk Southern Corporation

Norfolk Southern (NSC) trades at $316.99, up 1.21% with bullish technical indicators and strong institutional support. The company demonstrates solid fundamentals with consistent earnings beats, a 21.02% net income margin, and robust cash flow from operations. Recent news highlights momentum for the proposed Union Pacific merger, with regulatory review advancing and over 500 customer endorsements supporting the combination's potential benefits.

NSC presents a favorable risk-reward profile with analyst consensus target of $361.86 offering 14% upside. Key opportunities include freight share gains from trucking and merger synergies, while risks involve fuel price pressures and regulatory hurdles for the combination. The stock remains well-positioned for long-term growth with dividend stability.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NSC

No sentiment data available yet.

VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Norfolk Southern Corporation

Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.

Read more on NSC →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →